Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies - Luna, G; Alping, P; Burman, J; Fink, K; Fogdell-Hahn, A; Gunnarsson, M (JAMA Neurol, 2020)